SAMBA HIV Semiquantitative Test, a New Point-of-Care Viral-Load-Monitoring Assay for Resource-Limited Settings

ABSTRACT Routine viral-load (VL) testing of HIV-infected individuals on antiretroviral therapy (ART) is used to monitor treatment efficacy. However, due to logistical challenges, implementation of VL has been difficult in resource-limited settings. The aim of this study was to evaluate the performance of the SAMBA semi-Q (simple amplification-based assay semiquantitative test for HIV-1) in London, Malawi, and Uganda. The SAMBA semi-Q can distinguish between patients with VLs above and below 1,000 copies/ml. The SAMBA semi-Q was validated with diluted clinical samples and blinded plasma samples collected from HIV-1-positive individuals. SAMBA semi-Q results were compared with results from the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 test, v2.0. Testing of 96 2- to 10-fold dilutions of four samples containing HIV-1 subtype C as well as 488 samples from patients in the United Kingdom, Malawi, and Uganda yielded an overall accuracy for the SAMBA semi-Q of 99% (95% confidence interval [CI], 93.8 to 99.9%) and 96.9% (95% CI 94.9 to 98.3%), respectively, compared to to the Roche test. Analysis of VL data from patients in Malawi and Uganda showed that the SAMBA cutoff of 1,000 copies/ml appropriately distinguished treated from untreated individuals. Furthermore, analysis of the viral loads of 232 patients on ART in Malawi and Uganda revealed similar patterns for virological control, defined as either <1,000 copies/ml (SAMBA cutoff) or <5,000 copies/ml (WHO 2010 criterion; WHO, Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach, 2010). This study suggests that the SAMBA semi-Q has adequate concurrency with the gold standard measurements for viral load. This test can allow VL monitoring of patients on ART at the point of care in resource-limited settings.

[1]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[2]  J. Gallant,et al.  Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Stephenson.  Cheaper HIV drugs for poor nations bring a new challenge: monitoring treatment. , 2002, JAMA.

[4]  L. Pinoges,et al.  Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda , 2009, BMC infectious diseases.

[5]  S. Lawn,et al.  Monitoring of antiretroviral therapy in low-resource settings , 2008, The Lancet.

[6]  D. S. Sivia,et al.  Data Analysis , 1996, Encyclopedia of Evolutionary Psychological Science.

[7]  M. Hernán,et al.  Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa , 2012, Journal of acquired immune deficiency syndromes.

[8]  Helen H. Lee,et al.  Simple amplification-based assay: a nucleic acid-based point-of-care platform for HIV-1 testing. , 2010, The Journal of infectious diseases.

[9]  E. Szumilin,et al.  Vital status of pre‐ART and ART patients defaulting from care in rural Malawi , 2010, Tropical medicine & international health : TM & IH.

[10]  L. Ferradini,et al.  Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. , 2004, AIDS.

[11]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[12]  Beth Chaplin,et al.  Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  Tara L. Kieffer,et al.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. , 2005, JAMA.

[14]  R. Schall,et al.  Comparative Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2 Test Using the TaqMan 48 Analyzer and the Abbott RealTime HIV-1 Assay , 2010, Journal of Clinical Microbiology.

[15]  A. Calmy,et al.  Patient needs and point-of-care requirements for HIV load testing in resource-limited settings. , 2010, The Journal of infectious diseases.

[16]  Tara L. Kieffer,et al.  HIV-1 viral load blips are of limited clinical significance. , 2006, The Journal of antimicrobial chemotherapy.

[17]  B. Chi,et al.  Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.

[18]  Cheryl Jennings,et al.  HIV-1 Viral Load Assays for Resource-Limited Settings , 2006, PLoS medicine.

[19]  William P. Whery,et al.  A NATIONAL DEPARTMENT OF HEALTH. , 1907, Science.

[20]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .